Qiagen (NYSE:QGEN) Announces Earnings Results

Qiagen (NYSE:QGEN) announced its quarterly earnings data on Wednesday. The company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.60 by $0.02, Zacks reports. Qiagen had a net margin of 19.16% and a return on equity of 14.40%. The business’s revenue for the quarter was up .2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.60 earnings per share. Qiagen updated its FY 2026 guidance to 2.430- EPS.

Qiagen Stock Down 0.9%

QGEN stock traded down $0.40 during midday trading on Wednesday, reaching $41.93. 2,037,433 shares of the company were exchanged, compared to its average volume of 2,431,495. Qiagen has a 1-year low of $32.53 and a 1-year high of $57.81. The company has a market cap of $8.64 billion, a price-to-earnings ratio of 21.90, a price-to-earnings-growth ratio of 4.22 and a beta of 0.63. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.57 and a current ratio of 3.21. The stock’s 50-day simple moving average is $39.10 and its 200 day simple moving average is $41.77.

Qiagen Increases Dividend

The firm also recently announced an annual dividend, which was paid on Tuesday, July 14th. Stockholders of record on Tuesday, July 7th were given a dividend of $0.35 per share. This is a boost from Qiagen’s previous annual dividend of $0.26. The ex-dividend date of this dividend was Tuesday, July 7th. This represents a dividend yield of 90.0%. Qiagen’s dividend payout ratio is 18.32%.

Hedge Funds Weigh In On Qiagen

A number of hedge funds and other institutional investors have recently made changes to their positions in QGEN. Evergreen Capital Management LLC purchased a new position in Qiagen during the 2nd quarter worth $246,000. O Shaughnessy Asset Management LLC purchased a new stake in shares of Qiagen during the 4th quarter worth approximately $242,000. United Services Automobile Association purchased a new stake in Qiagen during the first quarter worth $239,000. Quadrant Capital Group LLC grew its stake in Qiagen by 26.5% in the 3rd quarter. Quadrant Capital Group LLC now owns 5,273 shares of the company’s stock valued at $236,000 after acquiring an additional 1,105 shares during the last quarter. Finally, Captrust Financial Advisors purchased a new position in shares of Qiagen during the 2nd quarter worth approximately $221,000. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on QGEN shares. Weiss Ratings downgraded shares of Qiagen from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, May 29th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $43.00 price objective on shares of Qiagen in a research report on Thursday, April 30th. Citigroup restated a “hold” rating on shares of Qiagen in a research report on Monday, May 18th. TD Cowen reissued a “hold” rating on shares of Qiagen in a report on Wednesday, July 15th. Finally, Stifel Nicolaus set a $36.00 price target on shares of Qiagen and gave the stock a “hold” rating in a research note on Monday, May 18th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Qiagen presently has a consensus rating of “Hold” and an average price target of $43.34.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.